Cell and gene therapies are redefining the frontiers of medicine, offering new possibilities to patients who previously had limited or no therapeutic options. Their promise depends not only on scientific innovation, but on precise execution across regulatory, clinical, manufacturing, and patient supply.
Linical enables the delivery of cell and gene therapy trials through integrated operational expertise across these interconnected domains.
This shift introduces a new level of complexity. Regulatory strategy, clinical execution, data generation, patient supply logistics, and device integration for administration are no longer sequential steps; they must operate in full alignment.
Linical brings deep operational experience as a strategic global CRO partner for advanced therapies, supporting biotechs in accelerating innovative treatments to patients.
Cell and gene therapy programs present challenges that require specialized expertise and operational rigor:
• Small and highly selected patient populations
• Patient specific and time sensitive supply chains
• Complex delivery and administration approaches
• Intensive regulatory requirements, particularly in Europe within ATMP and GMO frameworks
• Rapid data driven early phase decision making
Linical translates these challenges into structured and controlled operational plans, with dedicated oversight across regulatory, clinical operations, and patient supply.
In cell and gene therapy trials, patient supply logistics are inseparable from chain of identity and chain of custody for human tissues. Linical manages patient specific workflows from clinical site collection through manufacturing, quality testing, transport, and final administration, ensuring continuous traceability, data integrity, and regulatory compliance at every step.
Our teams work closely with sites, couriers, manufacturers, and device providers to implement robust processes, with real time oversight, deviation management, and reconciliation across clinical, logistics, and manufacturing data.
Many gene therapies rely on a medical device for administration, adding further complexity to trial execution. Linical manages the integrated delivery of programs that incorporate a device, including:
• Coordination of device supply, qualification, and accountability
• Integration of device handling and administration within clinical protocols
• Support for site training and operational readiness
• Monitoring and accountability across investigational product and device
• Alignment with regulatory requirements across medicinal product and device frameworks
By managing the combined operational requirements of product and device, Linical ensures consistent execution and patient safety.
Linical combines global capabilities with a biotech oriented mindset, emphasizing flexibility and close collaboration. This approach enables:
• Navigation of ATMP regulatory pathways with support for CTA and IMPD strategies
• Efficient early phase execution, including cohort escalation and interim analyses
• Integrated patient supply coordination aligned with clinical timelines and site readiness
• High quality data delivery within demanding timelines
• Operational continuity despite evolving program needs
This model supports rapid decision making during cohort escalation, interim safety reviews, and protocol adaptations driven by emerging clinical or manufacturing insights.
Europe remains a critical yet complex environment for gene therapy development. Linical supports sponsors through:
• Preparation of robust and submission ready dossiers
• Management of CTIS submissions alongside country specific GMO processes
• Anticipation of regulatory constraints to optimize study start timelines
This integrated approach reduces delays and mitigates development risk.
Success in cell and gene therapy depends on speed without compromise on quality. Linical’s subject matter experts combine scientific expertise, operational adaptability, and global reach to support sponsors throughout their development journey, ensuring alignment across regulatory, clinical, and logistical dimensions.
As the field continues to mature, sponsors are seeking partners who combine scientific understanding with operational excellence, and who can execute complex programs with precision.
Linical’s positioning reflects this evolution:
Right Size, Right Reach, Right Team as a strategic global CRO partner for advanced therapies, accelerating the delivery of innovative treatments to patients.
Author:
Thierry Ingrand
Sr Director, Business Development
Co-Author:
Alison Messom PhD
Executive Vice President Global Operations